A lawsuit was filed on behalf of investors in Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 05/22/2018 -- An investor, who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR), filed a lawsuit over alleged violations of Federal Securities Laws by Esperion Therapeutics, Inc.
Investors who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) have certain options and for certain investors are short and strict deadlines running. Deadline: July 6, 2018. NASDAQ: ESPR investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The plaintiff alleges on behalf of purchasers of Esperion Therapeutics, Inc. (NASDAQ: ESPR) common shares between February 22, 2017 and May 1, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 22, 2017 and May 1, 2018, the defendants made false and/or misleading statements and/or failed to disclose that Esperion's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death, and that as a result of the foregoing, Esperion's public statements were materially false and misleading at all relevant times
On May 2, 2018, Esperion Therapeutics, Inc announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion Therapeutics, Inc reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) declined to $33.06 per share on May 3, 2018.
Those who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels